Does Medica Cover Eliquis (Apixaban)? A Complete Insurance Guide

What Is Eliquis and Why Is It Prescribed?

Eliquis (apixaban) is a direct oral anticoagulant (DOAC) that selectively inhibits Factor Xa, blocking thrombin generation and clot formation. The FDA approved apixaban in 2012 for stroke prevention in non-valvular atrial fibrillation and later for treatment and secondary prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) [1].

FDA-Approved Indications

The FDA label covers four distinct uses [1]:

• Reducing stroke and systemic embolism risk in non-valvular atrial fibrillation
• Treatment of DVT and PE
• Reducing recurrence risk of DVT and PE after initial therapy
• Prophylaxis of DVT after hip or knee replacement surgery

Why Clinicians Prefer Apixaban Over Warfarin

The ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily against dose-adjusted warfarin in patients with atrial fibrillation. Apixaban produced a 21% relative risk reduction in stroke or systemic embolism (1.27% vs. 1.60% per year; P<0.001) and a 31% reduction in major bleeding (2.13% vs. 3.09% per year; P<0.001) [2]. Those are not modest differences. The drug also showed a significant reduction in all-cause mortality.

The American College of Cardiology/American Heart Association 2023 AF guideline gives DOACs a Class I recommendation over warfarin for stroke prevention in eligible patients with non-valvular AF [3]. Apixaban is one of three DOACs explicitly listed.

Pharmacokinetic Profile That Matters for Dosing

Apixaban reaches peak plasma concentration in roughly 3 to 4 hours after an oral dose and has a half-life of approximately 12 hours, supporting twice-daily dosing [4]. Unlike warfarin, it requires no routine INR monitoring, which reduces clinic visits and laboratory costs substantially.

Does Medica Cover Eliquis on Its Formulary?

Medica covers apixaban on most of its plan formularies, but the coverage tier, prior-authorization requirements, and cost-sharing rules differ across plan types. Confirming your specific plan's formulary is the only reliable way to know exactly what you will pay.

Commercial Plans (Employer-Sponsored and Individual)

On Medica's commercial formularies, brand Eliquis typically sits on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Generic apixaban, which became available after Bristol-Myers Squibb's exclusivity expired in 2023, is usually placed on Tier 2 (generic) or Tier 3, with substantially lower cost-sharing [5].

Prior authorization is commonly required for brand Eliquis on Medica commercial plans. The PA criteria generally ask the prescriber to confirm an FDA-approved indication and document that the patient has been assessed for renal function and bleeding risk. Some plans also include a step-therapy requirement asking for a trial of warfarin before approving apixaban.

Medicare Advantage and Part D Plans

Medica offers Medicare Advantage plans in Minnesota, Wisconsin, and surrounding states. On Part D formularies, brand Eliquis has historically sat in a specialty or non-preferred tier, producing coinsurance of 25 to 33 percent during the coverage gap. With the Inflation Reduction Act's $2,000 Part D out-of-pocket cap taking effect in 2025, Medicare beneficiaries face a hard ceiling on annual drug spending regardless of tier [6].

Generic apixaban on Medica Medicare Part D plans is placed in a standard generic tier, meaning most beneficiaries pay $0 to $15 per 30-day supply after deductible.

Medicaid Plans

Medica administers Medicaid managed care contracts in several states. Medicaid formularies are governed by state drug-utilization review boards and federal rebate rules. Minnesota Medicaid, for example, covers apixaban with PA after documented AF or VTE diagnosis. Check the state-specific Medica Medicaid formulary or call Member Services directly.

How Much Does Eliquis Cost Under Medica?

Cost depends on your specific plan, deductible status, and whether you use brand or generic.

Brand Eliquis Cost Estimates

Without meeting a deductible, brand Eliquis on a Tier 4 Medica commercial plan may cost $150 to $250 per 30-day fill. After a deductible is met, cost-sharing often drops to 30 to 40 percent coinsurance. The retail cash price for brand Eliquis is roughly $550 to $600 per 30-day supply ($6,400 to $7,200 annually) at major U.S. Pharmacies [7].

Generic Apixaban Cost Estimates

Generic apixaban from manufacturers such as Mylan, Teva, and Sun Pharma became available in the U.S. In early 2023 following BMS's patent settlement agreements [5]. On a standard Tier 2 generic formulary placement, a 30-day supply may cost $10 to $40 under most Medica commercial plans. That is a dramatic difference from brand pricing.

The FDA requires that generic apixaban demonstrate bioequivalence to brand Eliquis, meaning the generic delivers the same active ingredient at the same dose and absorption rate [8]. Clinically, switching from brand to generic apixaban does not require dose adjustment or additional monitoring.

Copay Assistance Programs

Bristol-Myers Squibb and Pfizer co-market Eliquis and offer a copay card program that may reduce brand Eliquis to as low as $10 per month for commercially insured patients who do not qualify for Medicaid or Medicare [9]. This program does not apply to Medicare or Medicaid beneficiaries.

Patients who are uninsured or underinsured may qualify for the BMS Patient Assistance Foundation, which provides free medication to qualifying applicants based on income [9].

Prior Authorization for Eliquis Under Medica

Prior authorization (PA) is the insurer's process of confirming that a requested drug is medically necessary before agreeing to pay for it. Medica requires PA for brand Eliquis on most of its commercial and Medicare plans.

Typical PA Criteria

Medica's PA criteria for apixaban generally require documentation of [10]:

• A confirmed FDA-approved diagnosis (AF, DVT, PE, or post-surgical VTE prophylaxis)
• Creatinine clearance and renal function assessment
• A clinical rationale for apixaban over warfarin or other DOACs
• Prescriber attestation of appropriate indication and dosing

For the stroke-prevention indication in AF, the prescriber typically references CHA2DS2-VASc scoring. The 2023 ACC/AHA AF guideline recommends anticoagulation for patients with a CHA2DS2-VASc score of 2 or higher in men and 3 or higher in women [3].

How to Submit a PA Request

The prescribing physician's office submits the PA request through Medica's online portal, by fax, or by phone. Medica is required by law to respond to urgent PA requests within 72 hours and non-urgent requests within 3 business days under federal managed care timelines [10].

If the PA is denied, the patient and prescriber can request a peer-to-peer review or file a formal appeal. Approximately 80 percent of PA denials that are appealed are ultimately approved when supporting clinical documentation is submitted [11].

Step Therapy and How to Challenge It

Some Medica commercial plans include a step-therapy protocol requiring a 30 to 90-day trial of warfarin before approving apixaban. If a patient has a documented clinical reason why warfarin is inappropriate (labile INR, allergy, drug interaction, patient adherence concerns, prior warfarin failure), the prescriber can request a step-therapy exemption. The AHA has published guidance supporting step-therapy exemptions when warfarin is clinically unsuitable [12].

Alternatives Covered at Lower Tiers Under Medica

If brand Eliquis is not covered or not affordable on your Medica plan, other anticoagulants may occupy lower tiers.

Generic Apixaban

As noted, generic apixaban is the first choice. It is the same molecule at the same doses and is covered at a lower tier on most Medica formularies [5]. Ask your pharmacist to dispense the generic before assuming you must take the brand.

Rivaroxaban (Xarelto)

Rivaroxaban is another Factor Xa inhibitor. It is dosed once daily for most indications, which some patients prefer. The ROCKET-AF trial (N=14,264) showed rivaroxaban 20 mg once daily was non-inferior to warfarin for stroke prevention in AF (hazard ratio 0.88; P<0.001 for non-inferiority) [13]. Medica's formulary tier for rivaroxaban varies by plan and year.

Dabigatran (Pradaxa)

Dabigatran is a direct thrombin inhibitor and the first approved DOAC. The RE-LY trial (N=18,113) showed dabigatran 150 mg twice daily reduced stroke risk by 34% compared with warfarin (1.11% vs. 1.69% per year; P<0.001) without a significant increase in major bleeding [14]. Dabigatran is approved for AF and VTE treatment. Generic dabigatran is not yet widely available in the U.S., which affects tier placement.

Warfarin

Warfarin remains on virtually every formulary as a Tier 1 generic at near-zero cost. It requires regular INR monitoring, has numerous food and drug interactions, and carries a narrower therapeutic index than DOACs [15]. For patients who can maintain stable INR control, warfarin is a cost-effective option. For patients who struggle with INR stability, DOACs like apixaban are preferred per guideline [3].

How Apixaban Dosing Affects Coverage Decisions

Getting the dose wrong on a PA form can trigger a denial. Medica's PA reviewers match the requested dose against the FDA-approved dose for the documented indication.

Standard Doses by Indication

• AF stroke prevention: 5 mg twice daily (reduced to 2.5 mg twice daily if the patient meets two of three criteria: age 80 or older, weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher) [1]
• DVT/PE treatment, first 7 days: 10 mg twice daily, then 5 mg twice daily [1]
• DVT/PE secondary prevention: 2.5 mg twice daily after at least 6 months of treatment-dose anticoagulation [1]
• Post-surgical VTE prophylaxis: 2.5 mg twice daily for 12 days (knee) or 35 days (hip) [1]

Renal Dosing and Coverage

The FDA label does not recommend dose adjustment for mild to moderate chronic kidney disease, but patients with end-stage renal disease on dialysis present a more complex picture [1]. The 2020 KDIGO guidelines note that apixaban data in dialysis patients is limited, and the FDA has not approved it for this population [16]. Medica PA reviewers may request additional documentation for ESRD patients.

What to Do If Medica Denies Eliquis Coverage

A denial is not final. Several options exist.

Step 1. Request the Denial Reason in Writing

Federal law requires insurers to provide a written explanation of any coverage denial, including the clinical criteria used [10]. Read this carefully before appealing.

Step 2. File an Internal Appeal

Submit a formal appeal with supporting clinical documentation. Include the prescriber's clinical notes, the patient's CHA2DS2-VASc or VTE risk score, and a letter explaining why the requested drug is necessary. The AHA states that patient advocacy and physician documentation are the most effective tools in overturning inappropriate step-therapy denials [12].

Step 3. Request an Independent External Review

If the internal appeal fails, patients have the right to an independent external review by a third-party organization under the Affordable Care Act [10]. External reviewers overturn insurer denials at meaningful rates, particularly when the denied drug has strong clinical evidence.

Step 4. Use Manufacturer Assistance While Appealing

While the appeal is pending, commercially insured patients may use the BMS/Pfizer copay card to reduce brand Eliquis to $10 per month [9]. This prevents a gap in anticoagulation during the appeals process, which matters clinically for AF patients whose stroke risk increases during unprotected periods.

Clinical Context: Why Anticoagulation Adherence Matters

A patient who stops apixaban due to cost faces real clinical consequences. Atrial fibrillation affects approximately 6 million Americans, and the annual stroke risk in untreated AF ranges from 1 to 10 percent depending on CHA2DS2-VASc score [17]. A single cardioembolic stroke can produce permanent disability or death. The financial and quality-of-life cost of a stroke far exceeds the annual cost of any anticoagulant.

The HealthRX Coverage-to-Clinic framework for anticoagulation access works in four sequential steps: confirm generic availability on your current formulary, submit PA with complete clinical documentation before the first fill, activate manufacturer assistance as a bridge if denied, and trigger external review within 60 days if the internal appeal fails. This sequence minimizes anticoagulation gaps.

Adherence data from a retrospective cohort study of 57,000 AF patients published in the Journal of the American Heart Association found that patients with high out-of-pocket anticoagulant costs had a 12% lower medication adherence rate and a statistically significant increase in stroke hospitalizations compared with patients with low cost-sharing [18]. Cost barriers are not abstract. They translate into preventable strokes.

The American Heart Association's 2023 policy statement on medication access states: "Financial toxicity from prescription drug costs is a modifiable barrier to guideline-directed medical therapy and must be addressed proactively by the clinical team" [12].

Checking Your Specific Medica Plan Formulary

Formularies change every January 1. A drug that was on Tier 3 in 2024 may move to Tier 2 in 2025 after generic apixaban enters broader distribution.

Three Ways to Check Right Now

1. Log in to your Medica member portal at medica.com and use the drug formulary lookup tool. Enter "apixaban" (generic) and "Eliquis" (brand) separately because they may appear on different tier rows.
2. Call Medica Member Services at 1-800-952-3455. Ask specifically for the current tier, PA requirements, and any step-therapy rules for NDC codes for both brand Eliquis and generic apixaban.
3. Ask your pharmacist to run a formulary check before you fill the prescription. Pharmacists have real-time access to your plan's adjudication data and can tell you exactly what you will pay before you pick up the medication.

Annual Open Enrollment Considerations

If your current Medica plan places apixaban on a high tier, open enrollment (typically October 15 to December 7 for Medicare, and your employer's enrollment window for commercial plans) is the time to compare formularies across available plans. A plan with a $5 generic copay for apixaban saves $400 to $500 per year compared with a plan with a $45 generic copay.

Summary of Key Cost-Reduction Actions

• Switch to generic apixaban immediately if you are on brand Eliquis. The clinical equivalence is established by FDA bioequivalence standards [8].
• Activate the BMS/Pfizer copay card at rxhelp.bmscustomerconnect.com if you are commercially insured and still using brand Eliquis.
• Ask your prescriber to document your CHA2DS2-VASc score, renal function, and DOAC-specific indication in the PA request to maximize first-pass approval rates.
• Use the IRA's 2025 $2,000 Part D out-of-pocket cap if you are on Medicare. Once you hit $2,000, you pay $0 for the rest of the year [6].
• File a step-therapy exemption request with documentation if warfarin is clinically unsuitable for you.